Neuroderm Ltd. shares (NASDAQ:NDRM) rose $1.24, or 10.9 percent, to close at $12.62 on Friday as investors welcomed the lifting of an FDA clinical hold that was blocking progress on U.S. studies of the company's Parkinson's disease treatments ND0612H and ND0612L.